ArticleArteriosclerosis, thrombosis, and vascular biology2022
Dichotomous Roles of Smooth Muscle Cell-Derived MCP1 (Monocyte Chemoattractant Protein 1) in Development of Atherosclerosis.
Article in Arteriosclerosis, thrombosis, and vascular biology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 30 citations in OpenAlex.
- Metabolic control of smooth muscle cell phenotype switching in atherosclerosis.Science advances · 2026Article
- Atherosclerotic Cardiovascular Disease and Cancer.Immunological reviews · 2026Review
- Smooth Muscle Cell Cytoglobin is a Negative Regulator of Atherosclerotic Fibrous Cap Development.bioRxiv : the preprint server for biology · 2026Article
- Monocyte Chemokines Enhance Atherosclerotic Plaque Necrosis After Bacterial Kidney Infection.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026Article
- IRF7 orchestrates maladaptive smooth muscle cell phenotype switching in atherosclerosis.Precision clinical medicine · 2026Article
- Targeting vascular inflammation and endothelial dysfunction with nanobodies: emerging therapeutic strategies for cardiovascular disease.Frontiers in immunology · 2026Review
- PRDM16 regulates smooth muscle cell identity and atherosclerotic plaque composition.Nature cardiovascular research · 2025Article
- Highly differentiated T cells link systemic and vascular inflammation in a mouse model of recurrent psoriasis.Frontiers in immunology · 2025Article
- Chronic inflammation and vascular cell plasticity in atherosclerosis.Nature cardiovascular research · 2024Review
- A combined analysis of bulk RNA-seq and scRNA-seq was performed to investigate the molecular mechanisms associated with the occurrence of myocardial infarction.BMC genomics · 2024Article
- Article
- Network-based prioritization and validation of regulators of vascular smooth muscle cell proliferation in disease.Nature cardiovascular research · 2024Article
- Chemokine CCL2 promotes cardiac regeneration and repair in myocardial infarction mice via activation of the JNK/STAT3 axis.Acta pharmacologica Sinica · 2024Article
- Conditional deletion ofAtherosclerosis plus · 2024Article
- Re-analysis of single-cell transcriptomics reveals a critical role of macrophage-like smooth muscle cells in advanced atherosclerotic plaque.Theranostics · 2024Article
- Phenotypic Switching of Vascular Smooth Muscle Cells in Atherosclerosis.Journal of the American Heart Association · 2023Review
- Mural cell-derived chemokines provide a protective niche to safeguard vascular macrophages and limit chronic inflammation.Immunity · 2023Article
- Reelin through the years: From brain development to inflammation.Cell reports · 2023Review
- Response by Owens and Deaton to Letter Regarding Article, "Dichotomous Roles of Smooth Muscle Cell-Derived MCP1 (Monocyte Chemoattractant Protein 1) in Development of Atherosclerosis".Arteriosclerosis, thrombosis, and vascular biology · 2023Article
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundSmooth muscle cells (SMCs) in atherosclerotic plaque take on multiple nonclassical phenotypes that may affect plaque stability and, therefore, the likelihood of myocardial infarction or stroke. However, the mechanisms by which these cells affect stability are only beginning to be explored.
methodsIn this study, we investigated the contribution of inflammatory MCP1 (monocyte chemoattractant protein 1) produced by both classical Myh11 (myosin heavy chain 11)
resultsWe show that loss of MCP1 in all Myh11
conclusionsMCP1 produced by classical SMCs influences monocyte levels beginning early in disease and was atheroprotective, while MCP1 produced by the Lgals3-transitioned subset of SMCs exacerbated plaque pathogenesis in late-stage disease. Results are the first to determine the function of Lgals3-transitioned inflammatory SMCs in atherosclerosis and highlight the need for caution when considering therapeutic interventions involving MCP1.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.